Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

This study has been completed.
Sponsor:
Collaborator:
Hammersmith Hospitals NHS Trust
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230659
First received: September 29, 2005
Last updated: May 28, 2015
Last verified: September 2005
  Purpose

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.


Condition Intervention Phase
Telangiectasia, Hereditary Hemorrhagic
Other: Blood sample to be taken.
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Investigation of Coagulation Parameters in Hereditary Haemorrhagic

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 100
Study Start Date: August 2004
Study Completion Date: July 2008
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
HHT patients
Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
Other: Blood sample to be taken.
Blood sample to be taken.
Other Name: Blood sample to be taken.
Controls
People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
Other: Blood sample to be taken.
Blood sample to be taken.
Other Name: Blood sample to be taken.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with HHT and normal controls

Exclusion Criteria:

  • Previous thrombosis, recent ill health
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230659

Locations
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Hammersmith Hospitals NHS Trust
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

Publications:
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT00230659     History of Changes
Other Study ID Numbers: IC/CLS6
Study First Received: September 29, 2005
Last Updated: May 28, 2015
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Telangiectasia, Hereditary Hemorrhagic
Telangiectasis
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Vascular Diseases
Vascular Malformations

ClinicalTrials.gov processed this record on July 30, 2015